Oncodesign – a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment – won the 4th European Small and Mid-Cap Awards in the “Rising Star” category. The award was presented to Oncodesign at a ceremony in Brussels on November 17, 2016.
The European Small and Mid-Cap Awards were set up to highlight the best European Small and Mid-Sized Companies that have gained access to capital markets via an Initial Public Offering (IPO). This is a joint initiative of the European Commission, leading European securities exchanges and EuropeanIssuers.
The four winners were chosen by an independent jury from amongst a very high standard of entries from across Europe.
“We are very proud to receive this award. It is a recognition for all employees of Oncodesign without whom we would not have come to this stage. All of us share one mission: to discover new innovative treatments for cancer and serious diseases patients with no known therapies,” said Dr Philippe Genne, CEO and founder of Oncodesign.